

Breast Cancer Therapeutics Market Forecasts to 2034 – Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography

<https://marketpublishers.com/r/BDF173D8D5D7EN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: BDF173D8D5D7EN

Abstracts

According to Statistics MRC, the Global Breast Cancer Therapeutics Market is accounted for \$37.9 billion in 2026 and is expected to reach \$77.3 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Breast cancer therapeutics refers to the various treatments and interventions designed to manage, treat, or cure breast cancer. These therapeutics encompass a wide range of approaches, including surgery, chemotherapy, radiation therapy, targeted therapy, hormone therapy, immunotherapy, and newer emerging treatments like precision medicine and gene therapy. Therapeutic approaches often vary based on the stage of the cancer, its specific characteristics, and the individual patient's health and preferences.

According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The increasing prevalence of breast cancer globally prompts greater demand for

therapeutic options, spurring research and development efforts. Emerging technologies offer more targeted therapies, improving efficacy and reducing side effects. The growing awareness of early detection emphasizes the need for comprehensive treatment solutions, creating a conducive environment for market expansion. This surge in demand encourages competitive pricing strategies and fosters collaborations for enhanced patient care, propelling the market forward.

Restraint:

Adverse effects of therapeutics

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. Side effects of treatments can be severe and impact the patient's quality of life.

Opportunity:

Expanding geriatric population

With an aging population worldwide, there's a higher incidence of cancer, including breast cancer, leading to a greater demand for therapeutic options. With advanced age being a primary risk factor for breast cancer, the growing demographic of older individuals creates a larger pool of potential patients. Additionally, increased awareness and improved screening methods within this population offer opportunities for early detection and intervention, fostering better treatment outcomes and market expansion.

Threat:

High cost of therapies

Many advanced breast cancer treatments are expensive, limiting access for patients without adequate insurance coverage or financial resources. Affordability issues lead to unequal access to innovative medications, impacting treatment efficacy and patient outcomes. High expenses also burden healthcare systems, constraining resources and potentially limiting research and development of newer, more accessible therapies. These cost barriers hinder the growth of the market.

Covid-19 Impact:

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. The pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients.

The targeted therapy segment is expected to be the largest during the forecast period

The targeted therapy segment is expected to be the largest during the forecast period. Targeted therapy in breast cancer offers precise treatment, attacking specific molecules crucial for cancer growth while sparing healthy cells. It enhances efficacy with reduced side effects compared to traditional treatments, improving patient outcomes. Their ability to prevent cancer's progression by pinpointing distinct pathways amplifies treatment effectiveness, promising better survival rates and a higher quality of life for patients.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies play a pivotal role in breast cancer therapeutics by ensuring timely access to specialized medications, optimizing drug regimens, and providing personalized care. They facilitate seamless coordination between healthcare teams, ensuring accurate dosing and monitoring of treatments, thereby enhancing patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to government initiatives, and the presence of key pharmaceutical companies. The region is dynamic, with ongoing research, clinical trials, and collaborations between pharmaceutical companies and research institutions driving innovation. It's also supported by strong healthcare infrastructure and favorable reimbursement policies, allowing patients access to advanced treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors, including increasing awareness, advancements in technology and improved access to healthcare facilities. There's also a growing trend toward personalized medicine, where treatments are tailored based on the specific characteristics of the tumor. The adoption of advanced diagnostic tools and treatment modalities has significantly improved patient outcomes.

Key players in the market

Some of the key players in Breast Cancer Therapeutics market include Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, Perkin Elmer Inc., Pfizer Inc., Puma Biotechnology Inc., NanoString Technologies Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Clovis Oncology.

Key Developments:

In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.

In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.

Therapies Covered:

Hormonal Therapy

Targeted Therapy

Chemotherapy

Immunotherapy

Other Therapies

Cancer Types Covered:

HER2+

Hormone Receptor

Distribution Channels Covered:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

End Users Covered:

Research Institutions

Diagnostic Centers

Clinics

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY THERAPY

- 5.1 Introduction
- 5.2 Hormonal Therapy
 - 5.2.1 Aromatase Inhibitors
 - 5.2.2 Estrogen Receptor Downregulators (ERDs)
 - 5.2.3 Selective Estrogen Receptor Modulators (SERMs)
- 5.3 Targeted Therapy
 - 5.3.1 Trastuzumab
 - 5.3.2 Pertuzumab
 - 5.3.3 Everolimus
 - 5.3.4 Ado-Trastuzumab Emtansine
 - 5.3.5 Palbociclib
 - 5.3.6 Ribociclib
 - 5.3.7 Olaparib
 - 5.3.8 Abemaciclib
- 5.4 Chemotherapy
- 5.5 Immunotherapy
- 5.6 Other Therapies

6 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY CANCER TYPE

- 6.1 Introduction
- 6.2 HER2+
- 6.3 Hormone Receptor

7 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

- 7.1 Introduction
- 7.2 Retail Pharmacies
- 7.3 Hospital Pharmacies
- 7.4 Online Pharmacies

8 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY END USER

- 8.1 Introduction
- 8.2 Research Institutions
- 8.3 Diagnostic Centers
- 8.4 Clinics

8.5 Other End Users

9 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

9.1 Introduction

9.2 North America

9.2.1 US

9.2.2 Canada

9.2.3 Mexico

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 Italy

9.3.4 France

9.3.5 Spain

9.3.6 Rest of Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 New Zealand

9.4.6 South Korea

9.4.7 Rest of Asia Pacific

9.5 South America

9.5.1 Argentina

9.5.2 Brazil

9.5.3 Chile

9.5.4 Rest of South America

9.6 Middle East & Africa

9.6.1 Saudi Arabia

9.6.2 UAE

9.6.3 Qatar

9.6.4 South Africa

9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

11 COMPANY PROFILING

- 11.1 Exelixis Inc.
- 11.2 F. Hoffmann La Roche Ltd.
- 11.3 GlaxoSmithKline Plc
- 11.4 Merck and Co. Inc.
- 11.5 Sanofi
- 11.6 Teva Pharmaceutical Industries Ltd.
- 11.7 Viatriis Inc.
- 11.8 Novartis AG
- 11.9 Perkin Elmer Inc.
- 11.10 Pfizer Inc.
- 11.11 Puma Biotechnology Inc.
- 11.12 NanoString Technologies Inc.
- 11.13 Daiichi Sankyo Co. Ltd.
- 11.14 Eisai Co. Ltd.
- 11.15 Eli Lilly and Co.
- 11.16 AbbVie Inc.
- 11.17 Amgen Inc.
- 11.18 Bristol Myers Squibb
- 11.19 Clovis Oncology

List Of Tables

LIST OF TABLES

Table 1 Global Breast Cancer Therapeutics Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Breast Cancer Therapeutics Market Outlook, By Therapy (2023-2034) (\$MN)

Table 3 Global Breast Cancer Therapeutics Market Outlook, By Hormonal Therapy (2023-2034) (\$MN)

Table 4 Global Breast Cancer Therapeutics Market Outlook, By Aromatase Inhibitors (2023-2034) (\$MN)

Table 5 Global Breast Cancer Therapeutics Market Outlook, By Estrogen Receptor Downregulators (ERDs) (2023-2034) (\$MN)

Table 6 Global Breast Cancer Therapeutics Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2023-2034) (\$MN)

Table 7 Global Breast Cancer Therapeutics Market Outlook, By Targeted Therapy (2023-2034) (\$MN)

Table 8 Global Breast Cancer Therapeutics Market Outlook, By Trastuzumab (2023-2034) (\$MN)

Table 9 Global Breast Cancer Therapeutics Market Outlook, By Pertuzumab (2023-2034) (\$MN)

Table 10 Global Breast Cancer Therapeutics Market Outlook, By Everolimus (2023-2034) (\$MN)

Table 11 Global Breast Cancer Therapeutics Market Outlook, By Ado-Trastuzumab Emtansine (2023-2034) (\$MN)

Table 12 Global Breast Cancer Therapeutics Market Outlook, By Palbociclib (2023-2034) (\$MN)

Table 13 Global Breast Cancer Therapeutics Market Outlook, By Ribociclib (2023-2034) (\$MN)

Table 14 Global Breast Cancer Therapeutics Market Outlook, By Olaparib (2023-2034) (\$MN)

Table 15 Global Breast Cancer Therapeutics Market Outlook, By Abemaciclib (2023-2034) (\$MN)

Table 16 Global Breast Cancer Therapeutics Market Outlook, By Chemotherapy (2023-2034) (\$MN)

Table 17 Global Breast Cancer Therapeutics Market Outlook, By Immunotherapy (2023-2034) (\$MN)

Table 18 Global Breast Cancer Therapeutics Market Outlook, By Other Therapies

(2023-2034) (\$MN)

Table 19 Global Breast Cancer Therapeutics Market Outlook, By Cancer Type

(2023-2034) (\$MN)

Table 20 Global Breast Cancer Therapeutics Market Outlook, By HER2+ (2023-2034)

(\$MN)

Table 21 Global Breast Cancer Therapeutics Market Outlook, By Hormone Receptor

(2023-2034) (\$MN)

Table 22 Global Breast Cancer Therapeutics Market Outlook, By Distribution Channel

(2023-2034) (\$MN)

Table 23 Global Breast Cancer Therapeutics Market Outlook, By Retail Pharmacies

(2023-2034) (\$MN)

Table 24 Global Breast Cancer Therapeutics Market Outlook, By Hospital Pharmacies

(2023-2034) (\$MN)

Table 25 Global Breast Cancer Therapeutics Market Outlook, By Online Pharmacies

(2023-2034) (\$MN)

Table 26 Global Breast Cancer Therapeutics Market Outlook, By End User (2023-2034)

(\$MN)

Table 27 Global Breast Cancer Therapeutics Market Outlook, By Research Institutions

(2023-2034) (\$MN)

Table 28 Global Breast Cancer Therapeutics Market Outlook, By Diagnostic Centers

(2023-2034) (\$MN)

Table 29 Global Breast Cancer Therapeutics Market Outlook, By Clinics (2023-2034)

(\$MN)

Table 30 Global Breast Cancer Therapeutics Market Outlook, By Other End Users

(2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Breast Cancer Therapeutics Market Forecasts to 2034 – Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/BDF173D8D5D7EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDF173D8D5D7EN.html>